OXURION (EBR:OXUR) | WebDisclosure

Basculer en Français

10812	Companies
234240	Keywords
163037	Articles
125255	Press releases

Home
Companies
OXURION

PRESS RELEASE

published on 09/01/2025 at 18:00, 11 months 6 days ago

Oxurion bevestigt de vooruitgang van de onderhandelingen over haar strategie voor de diversificatie van de kasmiddelen; closing van de transactie wordt vóór 25 september 2025 verwacht
Oxurion NV (EURONEXT BRUSSEL: OXUR) kündigt positive Finanzierungsgespräche mit Atlas Special Opportunities an. Die Transaktion wird voraussichtlich vor dem 25. September 2025 abgeschlossen sein

Atlas Special Opportunities Oxurion NV Belgien Finanzierungsgespräche Pharmaunternehmen
BRIEF

published on 08/07/2025 at 18:05, 1 year ago

Oxurion reçoit des notifications de transparence d'UBS Group AG

Actions Transparence Investisseurs UBS Group AG Oxurion
BRIEF

published on 08/07/2025 at 18:05, 1 year ago

Oxurion receives transparency notifications from UBS Group AG

Investors Actions Transparency UBS Group AG Oxurion
PRESS RELEASE

published on 08/07/2025 at 18:00, 1 year ago

Oxurion ontvangt transparantiekennisgevingen van UBS Group AG
Oxurion NV (Euronext Brussel: OXUR) ontvangt transparantiekennisgevingen van UBS Group AG over aandelentransacties conform Belgische wetgeving. Oxurion, biofarmaceutisch bedrijf in Leuven, België, integreert innovatie en klinisch onderzoekstechnologieën

Transparantiekennisgevingen UBS Group AG Oxurion NV Biofarmaceutisch Belgische Wetgeving
PRESS RELEASE

published on 08/07/2025 at 18:00, 1 year ago

Oxurion Receives Transparency Notifications from UBS Group AG
Oxurion NV received transparency notifications from UBS Group AG regarding share holdings, in compliance with Belgian Transparency legislation. The company is a biopharmaceutical group focusing on therapeutic innovation and clinical research technologies

Clinical Research Biopharmaceutical UBS Group AG Oxurion NV Transparency Notifications
PRESS RELEASE

published on 08/07/2025 at 18:00, 1 year ago

Oxurion beëindigt RD-programma voor geografische maculaire degeneratie en focust op nieuwe CRO-activiteiten
Oxurion beendet präklinisches Forschungsprogramm zur Entwicklung neuer Therapieziele für altersbedingte Makuladegeneration (GA) und fokussiert auf CRO-Aktivitäten und Profitabilität. Integrierte Datenexpertise und externe Expansion im Fokus

Profitabilität Oxurion Präklinisches Forschungsprogramm GA CRO-Aktivitäten
BRIEF

published on 08/06/2025 at 18:05, 1 year ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC

Transparency Biopharmaceutical Shareholding Atlas Special Opportunities Oxurion
BRIEF

published on 08/06/2025 at 18:05, 1 year ago

Oxurion reçoit des notifications de transparence d'Atlas Special Opportunities II LLC

Actionnariat Transparence Biopharmaceutique Oxurion Opportunités Spéciales Atlas
PRESS RELEASE

published on 08/06/2025 at 18:00, 1 year ago

Oxurion Receives Transparency Notifications from Atlas Special Opportunities II LLC
Oxurion NV receives transparency notifications regarding changes in shareholding from Atlas Special Opportunities II, LLC as per Belgian Transparency legislation. Company combines therapeutic innovation with technology for new treatments

Clinical Research Shareholding Changes Oxurion NV Therapeutic Innovation Transparency Notifications
PRESS RELEASE

published on 08/06/2025 at 18:00, 1 year ago

Oxurion ontvangt transparantiekennisgevingen van Atlas Special Opportunities II LLC
Oxurion NV ontvangt transparantiekennisgevingen over aandelentransacties en stimuleert therapeutische innovatie in biofarmaceutica. Zie voor meer informatie www.oxurion.com

Aandelentransacties Transparantiekennisgevingen Oxurion NV Therapeutische Innovatie Biofarmaceutica

Accesswire

Published on 08/08/2026 at 00:00, 2 hours 40 minutes ago

Boron One Announces Change of Auditor
Published on 08/07/2026 at 23:15, 3 hours 25 minutes ago

Faraday Copper Reports Second Quarter 2026 Financial Results
Published on 08/07/2026 at 23:00, 3 hours 40 minutes ago

Rio Grande Resources Announces up to $2,500,000 Non-Brokered Private Placement Financing
Published on 08/07/2026 at 22:30, 4 hours 10 minutes ago

UraniumX Deploys $3.8 Million to Athabasca Basin Exploration
Published on 08/07/2026 at 22:15, 4 hours 25 minutes ago

Noram Lithium Engages 1353656 BC Ltd. for Marketing and Management Consulting Services

View all ACCESSWIRE

EQS Group

Published on 08/07/2026 at 23:21, 3 hours 19 minutes ago

EQS-Adhoc: Northern Data Group reports Q2 2026 including the adverse fair value movement on contingent consideration
Published on 08/07/2026 at 19:30, 7 hours 10 minutes ago

Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/07/2026 at 19:15, 7 hours 25 minutes ago

ABO Energy Agrees Sale of Its Polish and Hungarian Subsidiaries
Published on 08/07/2026 at 18:10, 8 hours 30 minutes ago

Stabilus SE: Andreas Jaeger steps down as Chief Financial Officer at his own request
Published on 08/07/2026 at 18:00, 8 hours 40 minutes ago

E-PANGO: Composition du capital au 31 juillet 2026

Les Echos

Published on 08/07/2026 at 18:54, 7 hours 46 minutes ago

Covivio - Déclaration des transactions sur actions propres réalisées du 03 août 2026 au 07 août 2026
Published on 08/07/2026 at 18:54, 7 hours 46 minutes ago

Covivio - Information on Treasury shares transactions between August 3rd, 2026, and August 7th, 2026
Published on 08/07/2026 at 18:40, 8 hours ago

Disclosure of transactions in own shares from August 3 to August 7, 2026
Published on 08/07/2026 at 18:40, 8 hours ago

Déclaration hebdomadaire d'opérations effectuées du 3 au 7 août 2026
Published on 08/07/2026 at 18:00, 8 hours 40 minutes ago

LANSON-BCC : Déclaration du nombre total des droits de vote et du nombre d’actions au 31 juillet 2026

View all LES ECHOS COMFI WIRE